Glucagon-like peptide-1: difference between revisions
Diff·revision 49 → 50·08:14, 5 May 2025
Difference between revision 49 and revision 50 of Glucagon-like peptide-1. 7 lines changed; the page grew by 977 bytes.
| Revision 49 — 09:08, 25 Apr 2025 SatietySunniva (talk) add figure 10,252 bytes +13 | Revision 50 — 08:14, 5 May 2025 A1c_Alder (talk) add figure 11,229 bytes +977 | ||
|---|---|---|---|
| 73 | {{seealso|GLP-1 receptor|Beta cell function}} | 73 | {{seealso|GLP-1 receptor|Beta cell function}} |
| 74 | 74 | ||
| + | 75 | == Impaired incretin response in disease == | |
| + | 76 | In type 2 diabetes the incretin effect is markedly attenuated. The dominant lesion appears to be loss of beta-cell responsiveness to GIP rather than deficient GLP-1 secretion, since pharmacological GLP-1 concentrations restore much of the insulin response whereas GIP does not.{{r|nauck1986,nauck2018}} This asymmetry is the reason the GLP-1 arm of the axis, and not the GIP arm, was pursued first as a monotherapy target — and it is also why the later demonstration that GIP co-agonism ''adds'' clinical benefit in [[Dual incretin agonist|dual agonists]] was regarded as surprising. | |
| + | 77 | ||
| 75 | == References == | 78 | == References == |
| 76 | {{reflist}} | 79 | {{reflist}} |
| ⋮ | ⋮ | ||
| 83 | <ref name="kreymann1987">Kreymann B, Williams G, Ghatei MA, Bloom SR. "Glucagon-like peptide-1 7–36: a physiological incretin in man." ''The Lancet'' 2(8571):1300–1304 (1987). PMID 2890903.</ref> | 86 | <ref name="kreymann1987">Kreymann B, Williams G, Ghatei MA, Bloom SR. "Glucagon-like peptide-1 7–36: a physiological incretin in man." ''The Lancet'' 2(8571):1300–1304 (1987). PMID 2890903.</ref> |
| 84 | <ref name="deacon1995">Deacon CF, Johnsen AH, Holst JJ. "Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo." ''Journal of Clinical Endocrinology and Metabolism'' 80(3):952–957 (1995). PMID 7883856.</ref> | 87 | <ref name="deacon1995">Deacon CF, Johnsen AH, Holst JJ. "Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo." ''Journal of Clinical Endocrinology and Metabolism'' 80(3):952–957 (1995). PMID 7883856.</ref> |
| + | 88 | ||
| + | 89 | == Further reading == | |
| + | 90 | * Holst JJ. "Discovery of the GLP-1 based drugs for the treatment of diabetes and obesity." ''Peptides'' (2024) — a participant's account of the pathway from isolation to clinic. | |
| + | 91 | * Campbell JE, Drucker DJ. "Pharmacology, physiology, and mechanisms of incretin hormone action." ''Cell Metabolism'' 17(6):819–837 (2013). | |
| 85 | 92 | ||
| 86 | == See also == | 93 | == See also == |